The present invention relates to the adenosine A3 receptor ligands of the general formula (I), within them favourably to the antagonists, to their salts, solvates, N-oxides and isomers, to the pharmaceutical compositions containing the compounds of the general formula (I), their salts, solvates, N-oxides and isomers, to the use of the compounds of the general formula (I), their salts, solvates, N-oxides and isomers, to the preparation of the compounds of the general formula (I), their salts, solvates, N-oxides and isomers, as well as to the new intermediates of the general formula (II), (VI), (XI), (XII) and (XV), and to the preparation thereof.Predmetni pronalazak se odnosi na ligande adenozin A3 receptora opšte formule (I), među njima, poželjno je na antagoniste, njihove soli, solvate, N-okside i izomere, na farmaceutske preparate koji sadrže jedinjenja prema opštoj formuli (I), njihove soli, solvate, N-okside i izomere, na upotrebu jedinjenja prema opštoj formuli (I), njihovih soli, solvata, N oksida i izomera, na dobijanje jedinjenja prema opštoj formuli (I), njihovih soli, solvata, N oksida i izomera kao i na nove intermedijere opšte formule (II), (VI), (XI), (XII) i (XV) i na njihovo dobijanje.
